OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
Company Details
- Employees
- 19
- Founded
- -
- Address
- Palo Alto, Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.orsobio.com
- HQ
- Palo Alto, CA
Orsobio Questions
Orsobio's website is http://www.orsobio.com
Orsobio's LinkedIn profile is https://www.linkedin.com/company/orsobio
Orsobio has
19 employees.
View email and phone details for 19
employees at Orsobio.
Orsobio's industry is
Biotechnology Research
Orsobio's top competitors are
Terremoto Biosciences,
Nura Bio,
Hoth Therapeutics, Inc,
Arsenal Biosciences, Inc.,
Gc Therapeutics,
858 Therapeutics,
Athira Pharma,
Gate Bioscience,
Vaxcyte,
Circle Pharma, Inc..
Orsobio's categories are Biotechnology Research
Orsobio's founding year is 2021
